ArkBio Announces FDA Clearance to Initiate Phase II Trial of AK0406 for Influenza Prevention
The study will test safety and immune response in adults as ArkBio advances AK0406 as a new influenza prevention option.
7 Articles
7 Articles
Morgan County Citizen
ArkBio Announces FDA Clearance to Initiate Phase II Trial of AK0406 for Influenza Prevention
SHANGHAI, Oct. 13, 2026 /PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced that the U.S. Food and Drug Administration (FDA) has granted its investigational new drug (IND) application for AK0406, a long-acting antiviral drug-Fc conjugate (AFC), enabling the…
ArkBio Announces FDA Clearance to Initiate Phase II Trial of AK0406 for Influenza Prevention - Business News Week
SHANGHAI, Oct. 13, 2026 /PRNewswire/ — Shanghai Ark Biopharmaceutical Co., Ltd. (“ArkBio”) today announced that the U.S. Food and Drug Administration (FDA) has granted its investigational new drug (IND) application for AK0406, a long-acting antiviral drug-Fc conjugate (AFC), enabling the company to initiate a phase II clinical trial for influenza prevention in general population in […] The post ArkBio Announces FDA Clearance to Initiate Phase II…
Coverage Details
Bias Distribution
- 67% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
